Inmagene Biopharmaceuticals is at the forefront of developing innovative therapies targeting immunological and inflammatory diseases. Their lead candidate, IMG-007, is a monoclonal antibody (mAb) that specifically targets the OX40 receptor, which is primarily found on activated T cells. This engineered mAb has a silenced antibody-dependent cell-mediated cytotoxicity (ADCC) function, reducing potential toxicities while extending its half-life, allowing for potential long-term maintenance therapy with infrequent dosing. Clinical trials have shown promising results for IMG-007 in treating moderate-to-severe atopic dermatitis and severe alopecia areata, demonstrating significant improvements in skin lesions and a favorable safety profile.

Additionally, Inmagene is advancing IMG-004, a selective and reversible Bruton’s tyrosine kinase (BTK) inhibitor designed for chronic inflammatory and autoimmune conditions. This oral medication has shown a favorable safety profile and long half-life in early clinical studies, suggesting the possibility of once-daily dosing. Another notable asset is IMG-008, an anti-IL-36R mAb developed through Inmagene's proprietary QuadraTek® platform, which enhances the drug's half-life and exposure, potentially allowing for more convenient dosing regimens. Overall, Inmagene's commitment to scientific innovation and clinical intelligence positions it to address significant unmet medical needs in the field of immunology.

United States

Inmagene is a global clinical-stage biotechnology company developing novel therapeutics for I&I diseases. The company’s highly differentiated clinical-stage pipeline has multiple candidates with best-in-class potential. The lead asset IMG-007, a non-depleting anti-OX40 mAb, is in two global Phase 2a clinical trials in atopic dermatitis and alopecia areata. IMG-004, a non-covalent reversible BTK inhibitor is in a Phase 1 multiple ascending dose (MAD) study. IMG-008, an in-house developed long-acting anti-IL-36R mAb is entering global Phase 1 clinical development.

Immune System Diseases

Infectious Diseases

Musculoskeletal Diseases

Skin Diseases

Inmagene Biopharmaceuticals

Alopecia areata

Atopic dermatitis

IMG-007

Antibodies

Biologics

Chronic spontaneous urticaria

Rheumatoid arthritis

IMG-004

Small Molecule Pharmaceuticals

Generalized pustular psoriasis

Hidradenitis suppurativa

IMG-008

California - South

California

Antibody Drug Conjugates

Therapeutic

Inmagene Biopharmaceuticals

Company Details